RALOXIFENE GxP Raloxifene hydrochloride 60 mg tablets, blister pack

Country: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

raloxifene hydrochloride, Quantity: 60 mg

Disponibbli minn:

MedTAS Pty Ltd

INN (Isem Internazzjonali):

Raloxifene hydrochloride

Għamla farmaċewtika:

Tablet, film coated

Kompożizzjoni:

Excipient Ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; glycine; colloidal anhydrous silica; polysorbate 80; povidone; titanium dioxide; hypromellose; Carnauba Wax; macrogol 400

Rotta amministrattiva:

Oral

Unitajiet fil-pakkett:

28 tablets

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

Raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.Raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

Sommarju tal-prodott:

Visual Identification: White to off-white, oval, biconvex, film coated tablets with 'C' on one side and '12' on other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

2014-01-14